SV
Savara Inc.
SVRA · NASDAQ
$5.37 -0.92% (-$0.05)
1M -3.42%
Market Cap $1.10B
P/E Ratio -
Div. Yield -
ROE 90.28%
Bulios Fair Price
$3.49
35.0% downside
Current Price
$5.37
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SVRA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
4 /100
Expensive P/B 7.66x
PEG N/A
P/E N/A
Growth
100 /100
Growing Book val. growth 23.52%
FCF growth N/A
EPS growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 72.50%
ROIC 82.30%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 10.13x
Debt/Equity 0.21x
Debt/Assets N/A
Stability
46 /100
Moderate Profitable years 0
Beta 0.25x
EPS volatility 17.68%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SVRA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Matthew Pauls
Employees
70
Headquarters
Yardley
Upcoming events
11 NOV
Earnings
Upcoming earnings report